Whalesbook
Toh bhai, kya hua hai exactly? KIMS Hospitals ne Amaravati, jo ki ek tier-2 city hai, wahan apna naya 500-bed ka super speciality hospital kholne ka plan bataya hai. Yeh Andhra Pradesh aur aas paas ke areas ke liye ek bada step hai jahan advanced medical care ki demand badh rahi hai. Is announcement ke baad, company ke share price mein 8.40% ki tezi aayi aur woh ₹777.85 par pahunch gaya. Company ne is naye hospital ke liye APCRDA se 60 saal ka land lease bhi pakka kar liya hai. Plus, foreign institutional investors (FIIs) ka stake bhi thoda badh kar 14.57% ho gaya hai March 2026 quarter mein, jo investors ka confidence dikhata hai.
Ab dekho, yeh tier-2 cities mein expansion karna market ka current trend hai, kyunki wahan quality healthcare ki zaroorat hai. Lekin yahan ek bada 'parantu' hai. KIMS ka market cap lagbhag ₹29,000 crore ke aas paas hai, aur unka P/E ratio 90 se 105 tak ja raha hai, jo industry average 43.5 se kaafi zyada hai. Is wajah se kuch analysts bol rahe hain ki stock 'overvalued' hai competitors jaise Aster DM Healthcare aur Fortis Healthcare ke comparison mein.
Company ne revenue toh badhaya hai, par jo naye hospitals khule hain (Maharashtra, Kerala, Karnataka mein), woh abhi loss mein chal rahe hain. Network occupancy bhi around 50-54% hai. Management ka kehna hai ki FY26 tak EBITDA margins 22%-25% tak pahunch jayega aur Average Revenue Per Occupied Bed (ARPOB) ₹50,000-₹55,000 tak ja sakta hai. FY27 tak 1,700 naye beds add karne ka plan hai, jisme ₹13-15 billion ka capital expenditure lagega.
Sabse badi chinta kya hai? Ek toh yeh high valuation. Doosra, company par debt bhi badh raha hai. March 2025 tak total debt (leases mila kar) ₹2,557 crore ho gaya tha, jo FY24 ke ₹1,355 crore se kaafi zyada hai. Gearing ratio 1.06x aur Net debt to PBILDT 3.10x ho gaya hai. Aur aage ₹2,500 crore ka capex bhi planned hai FY28 tak. Matlab, paisa toh lagega hi.
Purane projects mein bhi cost overruns hue hain, jaise Bengaluru mein plans change hone ke baad cost 50% badh gayi thi. Naye hospitals ko break-even hone mein 9 se 12 mahine lag sakte hain, jo short-term profits ko affect kar sakta hai. Aur haan, pehle bhi kuch incidents hue hain jaise SPANV Medisearch ko ₹306.97 crore ka income tax notice mila tha, aur medical negligence ke liye ₹25 Lacs ka pay out bhi karna pada tha.
Analysts mostly 'Strong Buy' rating de rahe hain aur target ₹760 se ₹804 ke beech mein de rahe hain. Lekin ek assessment April 2026 mein 'Strong Sell' rating bhi thi, jo general sentiment se bilkul alag hai. Toh thoda mix hai scene, bhai.